Bionano Genomics stock price target lowered to $6 by H.C. Wainwright

H.C. Wainwright has lowered its price target for Bionano Genomics (NASDAQ:BNGO) to $6 from $7, while maintaining a Buy rating. This adjustment is primarily due to an increased share count, despite the stock trading near its 52-week low and an InvestingPro analysis suggesting it may be undervalued. Bionano Genomics reported a revenue decline for Q4 2025 and the full year 2025, but management provided 2026 revenue guidance indicating potential topline growth of up to 16%.

Original reporting
Investing.com Canada · Stock Market
Published Apr 13, 2026, 11:43 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 13, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bionano Genomics stock price target lowered to $6 by H.C. Wainwright — source image
Decision brief

The 30-second read

$BNGOBearishMed
01

Why it matters

The lowered price target reflects short-term valuation adjustments; long-term prospects depend on execution of growth strategies.

02

Market read

The news is relevant for investors focusing on biotech and genomics sectors, especially those holding or considering Bionano Genomics shares.

03

What to watch

Potential upcoming catalysts, such as new product launches or partnerships, could offset current concerns and lead to upside surprises.

Timing: short to medium term

Background

Bionano Genomics reported revenue declines for Q4 2025 and full year 2025, but provided optimistic guidance for 2026, indicating potential growth despite recent setbacks.

Company-level read

Ticker impact

$BNGOBearishMedium confidence
Context

The news directly pertains to Bionano Genomics (NASDAQ:BNGO), affecting its stock outlook.

Expected impact

Potential short-term decline followed by stabilization or slight rebound as fundamentals remain positive.

Evidence & confidence

The downward price target suggests caution; however, the maintained Buy rating and positive revenue guidance indicate long-term potential. Technical levels near recent lows may support a rebound.

Market effects

The biotech and genomics sector may experience slight negative sentiment due to valuation adjustments.

Limited regional impact; primarily affecting North American biotech stocks.

Low; specific to Bionano Genomics and related sector.

Counterpoint

The revenue decline and increased share count could indicate underlying operational challenges, suggesting a cautious approach.

Key entities

  • Bionano Genomics

    A biotech firm specializing in genome analysis tools.

  • H.C. Wainwright

    An investment bank providing research and analysis on biotech stocks.

Related articles

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.